Announcements Trials
Browse Landscape

Phase

Phase 3 3

Status

Terminated 4Completed 4Recruiting 3Active not recruiting 3Withdrawn 1Not yet recruiting 1Available 1

Sponsor Class

INDUSTRY 2OTHER 1

Study Type

Interventional 3

Sponsor

Cancer Type

Genitourinary 3

Conditions

Urinary Bladder Neoplasms 5Anus Neoplasms 5Non-Muscle Invasive Bladder Neoplasms 3Carcinoma, Transitional Cell 3Rectal Neoplasms 1Locally Advanced Anal Canal Cancer 1HIV Infections 1Colorectal Neoplasms 1Breast Neoplasms 1Appendiceal Neoplasms 1Anal Canal Carcinoma 1

Interventions

pembrolizumab 15Nivolumab 10avelumab 9atezolizumab 8Gemcitabine 8Cisplatin 8Magnetic Resonance Spectroscopy 6durvalumab 5Specimen Handling 5Docetaxel 5Carboplatin 5Paclitaxel 4Ipilimumab 4tislelizumab 3sacituzumab govitecan 3enfortumab vedotin 3Taxes 3Pemetrexed 3Mitomycin 3eribulin 2erdafitinib 2cabozantinib 2Doxorubicin 2CTLA-4 Antigen 2ALT-803 2zimberelimab 1veliparib 1urelumab 1tazemetostat 1spartalizumab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Active not recruiting × Carcinoma, Transitional Cell × Mitomycin × Clear all
NCT05243550 2026-05-11

ENVISION

UroGen Pharma Ltd.

Phase 3 Active not recruiting
240 enrolled 20 charts 1 FDA
Genitourinary

Non-Muscle Invasive Bladder Neoplasms, Urinary Bladder Neoplasms, Carcinoma, Transitional Cell

NCT06331299 2026-01-15

UTOPIA

UroGen Pharma Ltd.

Phase 3 Active not recruiting
99 enrolled
Genitourinary

Non-Muscle Invasive Bladder Neoplasms, Urinary Bladder Neoplasms, Carcinoma, Transitional Cell

NCT06462001 2024-06-17

BCG + MMC: Adding Mitomycin C to BCG in High-risk, Non-muscle-invasive Bladder Cancer

Nottingham University Hospitals NHS Trust

Phase 3 Active not recruiting
500 enrolled
Genitourinary

Carcinoma, Transitional Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡